MedTech Business Intelligence.

This is the first edition of Innotech Recruit's quarterly BI newsletter. Each quarter I'll pull out what actually matters from the sector data (funding, regulatory shifts, commercial leadership movement) and tell you what it means for the decisions you are making now.

No padding. No filler. Straight to the point.

The funding headline is a contraction. The useful read is different.

Q1 2026 saw $2.41 billion raised across 78 deals. Down 33% in capital and 46% in deal volume year on year. The companies that are struggling to raise are early-stage with thin evidence and no reimbursement story. The mid-tier rounds that directly precede commercial build-out remained consistent. The market is more selective, not more closed.

What has changed: investors now treat commercial leadership in seat as a de-risking milestone equivalent to FDA clearance. Companies raising Series B without a credible VP Sales or CCO in active process are routinely seeing term sheets compressed. That is new behaviour, and it has direct implications for when to start a search.

In the US: the ASC migration is a commercial architecture problem, not a reimbursement update.

The CMS 2026 rule added more than 500 procedures to the ASC Covered Procedures List, including cardiac catheter ablation. That is not a policy footnote. It is a procurement architecture change. The clinical champion, the purchase decision hierarchy, and the value conversation in a physician-owned ASC are fundamentally different from a hospital cardiology department. Commercial teams built for IDN selling are not automatically equipped for it.

Cardiovascular, surgical robotics, and AI-enabled diagnostics are the three categories attracting the most commercial build-out activity right now. Each one has a different commercial leadership profile requirement. The wrong hire in any of them is expensive.

In the UK: the rules just changed, materially.

Two things happened in Q1 that together represent the most significant shift in NHS medtech market access in a generation.

From April 2026, NICE's Technology Appraisal programme covers medtech for the first time. A positive TA now means mandated adoption across NHS England and Wales: not a badge of quality, a commissioning instruction. The NHS annual medtech spend is approximately £13 billion. The companies with the evidence packages to qualify will have a different commercial conversation with NHS buyers than they had six months ago.

Alongside this, MHRA and NICE launched a joint aligned pathway in March 2026, closing the historic gap between regulatory approval and HTA evidence requirements. Products moving through it will reach patients three to six months faster. Companies that designed their clinical development programmes to satisfy both bodies simultaneously will benefit. Companies that treated NICE submission as the start of commercial preparation will not.

In Ireland: the Galway-to-Boston hiring window is open.

Ireland's BioInnovate cohort follows a predictable arc: University of Galway spin-out, Enterprise Ireland funding, EIC grant, Series A, FDA submission, US launch. The hiring window for VP-level commercial leadership typically opens 12 to 18 months after Series A. Several companies in the Galway cluster are in that window now.

The specific challenge: finding a VP Commercial who understands an Irish parent company and can build a US commercial operation from near-zero in the Boston corridor. That is a narrow profile. The lead time to find and close someone from the passive market is 90 to 120 days from brief to offer.

The full Q1 2026 BI report is on the Innotech website.

It covers the category spotlights in detail, the UK regulatory landscape, the HSE and Irish market access dynamics, and what the ZS observation about senior talent movement in motion actually means for your hiring window.